Close

LOGIN

Remember me
Not a member?
or
Connect using:
Why BS?

We encourage visitors to register on Business Standard. Registering on the site is absolutely Free and offers you the following benefits.

Free Daily E-newsletter

Breaking News Alerts in your Inbox

Post Comments and Share your Feedback

Your Personal Business Standard Page

Free Portfolio of Stocks, Equity and Commodities Derivatives

Access Premium Services

Receive Selective Offers from our Third Party Premium Advertisers

Get Invited to Business Standard Events

Close

FORGOT PASSWORD?

Not a member?

Ranbaxy reappoints Arun Sawhney as CEO & MD for 5 yrs

AGM has also approved the reappointment of Takashi Shoda as the director of the company

Read more on:    Ranbaxy | BSE | Arun Sawhney | Takashi Shoda
Related News

Drug major Ranbaxy Laboratories today said its shareholders have approved reappointment of Arun Sawhney as CEO and Managing Director of the company for a period of five years.

The shareholders of the company at their annual general meeting held here have "unanimously approved the reappointment of Arun Sawhney as CEO and MD of the company for a period of five years with effect from January 1, 2012...," Ranbaxy said in a filing to the BSE.

The AGM has also approved the reappointment of Takashi Shoda as the director of the company, it added.

Takashi Shoda was inducted as a director on the board of the company on December 19, 2008.

The AGM has also approved appointment of Percy K Shroff as the director of the company. He was inducted as a director on the board of the company on March 27, 2009 and his term had expired.

Shares of Ranbaxy Laboratories were today trading at Rs 501 in the afternoon trade on BSE, down 0.27% from its previous close.

Read more on:   
|
|
|

Read More

CoalMin identifies 54 blocks for allocation through auction

Amid controversies over allegations of irregularities in allocation of coal mines, the Coal Ministry has identified 54 blocks to be allocated to ...

Back to Top

Quick Links

Back to Top